Congestive hepatopathy and hypoxic hepatitis in heart failure: A cardiologist's point of view

International Journal of Cardiology

Volumn 166, Issue 3, 2013, Pages 554-558

  Kavoliuniene, Ausra ^a   Vaitiekiene, Audrone ^a   Cesnaite, Giedre ^a  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

Author keywords

Congestive hepatopathy; Hypoxic hepatitis; Severe heart failure

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALDOSTERONE ANTAGONIST; ALKALINE PHOSPHATASE; ALPHA 2 MACROGLOBULIN; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILIRUBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GALACTOSE; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; HYDRALAZINE; INDOCYANINE GREEN; INOTROPIC AGENT; ISOSORBIDE DINITRATE; LACTATE DEHYDROGENASE; PROTHROMBIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; BLOOD CLOTTING TEST; CARDIOLOGIST; CHOLESTASIS; CLINICAL PRACTICE; CONGESTIVE HEPATOPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG TOLERABILITY; ENZYME ACTIVITY; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEMODYNAMICS; HUMAN; HYPOKALEMIA; HYPOXIC HEPATITIS; KIDNEY FAILURE; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LIVER BIOPSY; LIVER BLOOD FLOW; LIVER DISEASE; LIVER FIBROSIS; LOW DRUG DOSE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SYMPTOMATOLOGY; ANIMAL; ANOXIA; BLOOD; CARDIOLOGY; HEPATITIS; METHODOLOGY; PHYSICIAN ATTITUDE; PROCEDURES;

ANIMALS; ANOXIA; CARDIOLOGY; HEART FAILURE; HEPATITIS; HUMANS; PHYSICIAN'S ROLE;

EID: 84885854989     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.05.003     Document Type: Review

References (39)

1. Vollmar B, Menger MD. The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. Physiol Rev 2009; 89(4): 1269-339.
2. Denis C, De Kerguennec C, Bernuau J, Beauvais F, Cohen Solal A. Acute hypoxic hepatitis ['liver shock']: still a frequently overlooked cardiological diagnosis. Eur J Heart Fail 2004; 6(5): 561-5.
3. Henrion J, Schapira M, Luwaert R, Colin L, Delannoy A, Heller FR. Hypoxic hepatitis clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 2003; 82(6): 392-406.
4. Birrer R, Takuda Y, Takara T. Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med 2007; 46(14): 1063-70.
5. Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med 2000; 109(2): 109-13.
6. Weisberg IS, Jacobson IM. Cardiovascular diseases and the liver. Clin Liver Dis 2011; 15(1): 1-20.
7. Giallourakis CC, Rosenberg PM, Friedman LS. The liver in heart failure. Clin Liver Dis 2002; 6(4): 947-67.
8. Naschitz JE, Slobodin G, Lewis RJ, Zuckerman E, Yeshurun D. Heart diseases affecting the liver and liver diseases affecting the heart Am Heart J 2000; 140(1): 111-20.
9. Vasconcelos LA, de Almeida EA, Bachur LF. Clinical evaluation and hepatic laboratory assessment in individuals with congestive heart failure. Arq Bras Cardiol 2007; 88(5): 590-5.
10. Lau GT, Tan HC, Kritharides L. Type of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitation. Am J Cardiol 2002; 90(12): 1405-9.
11. Van Deursen VM, Damman K, Hillege HL, van Beek AP, van Veldhuisen DJ, Voors AA. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail 2010; 16(1): 84-90.
12. Poelzl G, Eberl C, Achrainer H, et al. Prevalence and prognostic significance of elevated gamma-glutamytransferase in chronic heart failure. Circ Heart Fail 2009; 2(4): 294-302.
13. Lichtinghagen R, Bahr MJ. Noninvasive diagnosis of fibrosis in chronic liver disease. Expert Rev Mol Diagn 2004; 4(5): 715-26.
14. Brosnan ME, Brosnan JT. Hepatic glutamate metabolism: a tale of 2 hepatocytes. Am J Clin Nutr 2009; 90(3): 857S-61S.
15. Rappaport AM The microcirculatory hepatic unit. Microvasc Res 1973; 6: 212-28.
16. Fuhrmann V, Kneidinger N, Herkner H, et al. Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients. Intensive Care Med 2009; 35(8): 1397-405.
17. Toris GT, Bikis CN, Tsourouflis GS, Theocharis SE. Hepatic encephalopathy: an updated approach from pathogenesis to treatment. Med Sci Monit 2011; 17(2): RA53-63.
18. Cassidy WM, Reynolds TB. Serum lactate dehydrogenase in the differential diagnosis of acute hepatocellular injury. J Clin Gastroenterol 1994; 19(2): 118-21.
19. Astegiano M, Sapone N, Demarchi B, Rossetti S, Bonardi R, Rizzetto M. Laboratory evaluation of the patient with liver disease. Eur Rev Med Pharmacol Sci 2004; 8(1): 3-9.
20. Fuhrmann V, Jäger B, Zubkova A, Drolz A. Hypoxic hepatitis - epidemiology, pathophysiology and clinical management Wien Klin Wochenschr 2010; 122(5-6): 129-39.
21. Stravitz RT, Kramer AH, Davern T, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 2007; 35(11): 2498-508.
22. Henderson LM, Fales FW. Continuous-flow fluorometry of low galactose concentrations in blood or plasma. Clin Chem 1980; 26(2): 282-5.
23. Sakka SG, Reinhart K, Meier-Hellmann A. Comparison of invasive and noninvasive measurements of indocyanine green plasma disappearance rate in critically ill patients with mechanical ventilation and stable hemodynamics. Intensive Care Med 2000; 26(10): 1553-6.
24. Seibel A, Müller A, Sakka SG. Indocyanine green plasma disappearance rate for monitoring hepatosplanchnic blood flow. Intensive Care Med 2011; 37(2): 357-9.
25. Sakka SG, Reinhart K, Meier-Hellmann A. Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. Chest 2002; 122(5): 1715-20.
26. Myers RP, Cerini R, Sayegh R, et al. Cardiac hepatopathy: clinical, hemodynamic and histologic characteristics and correlations. Hepatology 2003; 37(2): 393-400.
27. Kuntz E, Kuntz HD. Hepatology: principles and practice. Heidelberg: Springer; 2006.
28. Szyguła-Jurkiewicz B, Wojnicz R, Lekston A, et al. Effect of elevated bilirubin levels on the long-term outcome in patients with chronic heart failure due to hypertension. Pol Arch Med Wewn 2007; 117(5-6): 227-33.
29. Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity [CHARM] program. Eur J Heart Fail 2009; 11(2): 170-7.
30. Gelow JM, Desai AS, Hochberg CP, Glickman JN, Givertz MM, Fang JC. Clinical predictors of hepatic fibrosis in chronic advanced heart failure. Circ Heart Fail 2010; 3: 59-64.
31. Stauber RE, Lackner C. Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. World J Gastroenterol 2007; 13(32): 4287-94.
32. Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005; 41(6): 1376-82.
33. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357(9262): 1069-75.
34. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23(7): 685-713.
35. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology, developed in collaboration with the Heart Failure Association of the ESC [HFA] and endorsed by the European Society of Intensive Care Medicine [ESICM]. Eur Heart J 2008; 29(19): 2388-442.
36. Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010; 16(6): 1-194.
37. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 2003; 362(9386): 772-6.
38. Russell SD, Rogers JG, Milano CA, et al. Renal and hepatic function improve in advanced heart failure patients during continuous flow support with the Heart-Mate II left ventricular assist device. Circulation 2009; 120(23): 2352-7.
39. Dichtl W, Vogel W, Dunst KM, et al. Cardiac hepatopathy before and after heart transplantation. Transpl Int 2005; 18(6): 697-702.